secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001140361-24-037511
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel's NexoBrid gets FDA approval for pediatric severe burn treatment
------------------------------------------------------------------------

- FDA approved NexoBrid for eschar removal in pediatric patients with deep partial- and full-thickness thermal burns.
- Approval based on Phase 3 CIDS trial and additional pediatric data from earlier studies.
- Target customer base expands to approximately 20 pediatric burn centers in the U.S.
- NexoBrid was previously approved for adults in December 2022; pediatric indication adds new revenue opportunity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000114036124037511/0001140361-24-037511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000114036124037511/ef20034225_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-037511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer